New method for characterising liposome formulated drugs
![](/46/pdcnewsitem/07/51/79/postnovapr26-imageB.jpg)
CF3 coupled with UV-Vis detection able to separate and quantify the amount of free drug in a liposome-drug product.
Postnova Analytics has published an application study that describes a new method for quantification of liposome encapsulated drug using Centrifugal Field-Flow Fractionation (CF3).
Nanoparticles, including liposomes, are increasingly used for delivery of drug molecules. During formulation of a liposome around a drug particle, a relatively large amount of free drug may remain unencapsulated and therefore not available for drug delivery via the liposomal carrier. For formulation groups adopting this drug delivery methodology it is important to quantify the amount of free versus encapsulated drug in a product to accurately determine the delivered dose of drug to a patient.
In this study, CF3 coupled with UV-Vis detection was shown to be able to separate and quantify the amount of free drug in a liposome-drug product. The separation data was verified using optical microscopy. The authors conclude that CF3 shows great promise for separation and quantification of drug particles, as the field of nanomedicine and liposomal drug delivery grows.
The Postnova CF2000 Series system is based on the CF3 principle using a centrifugal field as the driving force for the separation. Particles effected by this field are separated by dynamic diffusion based upon both their size and density. This unique feature allows researchers to separate different particle materials having the same particle size. The separation can be further optimized by the use of different eluents and rotation speed programs. The CF2000 has shown great utility for the separation of complex nanoparticle samples in application areas including pharmaceuticals, environmental research, food, cosmetics and agrochemicals.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance